Zynex, Inc. Revises Revenue Guidance for the Fourth Quarter and Provides Revenue Guidance for the Full Year of 2017
January 08, 2018 at 07:34 pm IST
Share
Zynex, Inc. provided earnings guidance for the fourth quarter and full year of 2017. For the fourth quarter, the company estimates the revenue to range between $7.5 and $8.0 million. The previous estimate was between $7.0 and $7.5 million.
For the full year 2017 revenue is now estimated to come in between $22.8 and $23.3 million compared to $13.3 million in 2016.
Zynex, Inc. develops, manufactures, markets and sells medical devices used for pain management and rehabilitation, as well as non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals. The Companyâs devices are intended for pain management to reduce reliance on medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current, neuromuscular electrical stimulation and transcutaneous electrical nerve stimulation. The Companyâs products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, E-Wave and M-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Distributed Complementary, which includes Comfortrac/Saunders, JetStream/Pain Management Technologies, LSO Back Braces and Bracing, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter and HemeOx tHb Oximeter.
ZYNEX, INC. 
